New promising data with ColoNode for colon cancer
Umeå University, has in collaboration with HiloProbe AB completed the first part of a new clinical study of its ColoNode biomarker test, which provides further important evidence for the product ColoNode’s benefits and usefulness in colon cancer.
“The results look promising”, says Lina Olsson, CEO of Hiloprobe AB